KM602

Xuanzhu Biopharmaceutical Co., Ltd. · Phase 1 active Biologic

KM602 is an investigational drug developed by Xuanzhu Biopharmaceutical Co., Ltd. It is currently in Phase 1 clinical trials for advanced solid tumors. No FDA label is available, and the drug has not yet been approved for any indication.

At a glance

Generic name	KM602
Sponsor	Xuanzhu Biopharmaceutical Co., Ltd.
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

KM602 CI brief — competitive landscape report
KM602 updates RSS · CI watch RSS
Xuanzhu Biopharmaceutical Co., Ltd. portfolio CI